Publications in OpenAlex of which a co-author is affiliated to this organization
All publications | By field | By subfield
All publications [Next]
| Title | DOI |
|---|---|
| https://doi.org/10.1056/nejmoa1908681 | Nintedanib in Progressive Fibrosing Interstitial Lung Diseases |
| https://doi.org/10.1177/1479164115570301 | Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®) |
| https://doi.org/10.1186/s12931-015-0276-5 | Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis |
| https://doi.org/10.1016/j.ejca.2011.11.001 | A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours |
| https://doi.org/10.1056/nejmoa2503643 | Nerandomilast in Patients with Progressive Pulmonary Fibrosis |
| https://doi.org/10.3168/jds.2019-17486 | Pathogen-specific risk factors in acute outbreaks of respiratory disease in calves |
| https://doi.org/10.1007/s40262-016-0417-0 | Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study |
| Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™). | |
| https://doi.org/10.1182/blood.v124.21.344.344 | Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects |
| https://doi.org/10.1186/s12931-021-01668-1 | Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases |
| https://doi.org/10.1016/j.vetmic.2020.108644 | Antimicrobial susceptibility of nine udder pathogens recovered from bovine clinical mastitis milk in Europe 2015–2016: VetPath results |
| https://doi.org/10.1186/s12931-022-01974-2 | Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial |
| https://doi.org/10.3389/fvets.2021.641441 | The Evaluation of Equine Allogeneic Tenogenic Primed Mesenchymal Stem Cells in a Surgically Induced Superficial Digital Flexor Tendon Lesion Model |
| https://doi.org/10.1136/bmjresp-2022-001580 | Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD) |
| https://doi.org/10.1016/s0733-5210(03)00022-5 | Phytosterol analysis and characterization in spelt (Triticum aestivum ssp. spelta L.) and wheat (T. aestivum L.) lipids by LC/APCI-MS |
| https://doi.org/10.1093/annonc/mdy241 | Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study |
| https://doi.org/10.1200/jgo.18.00216 | Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival |
| https://doi.org/10.3111/13696998.2013.766200 | Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium |
| https://doi.org/10.1093/annonc/mds633 | A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors |
| https://doi.org/10.3389/fvets.2021.668881 | Review: Mesenchymal Stem Cell Therapy in Canine Osteoarthritis Research: “Experientia Docet” (Experience Will Teach Us) |
| https://doi.org/10.1007/s10637-015-0223-9 | Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity |
| https://doi.org/10.2165/00044011-200424010-00003 | Long-Term Efficacy and Safety of Ipratropium Bromide plus Fenoterol via Respimat?? Soft Mist??? Inhaler (SMI) versus a Pressurised Metered-Dose Inhaler in Asthma |
| https://doi.org/10.1097/hs9.0000000000000617 | Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial |
| https://doi.org/10.1016/j.rmed.2012.09.006 | Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium |
| https://doi.org/10.1016/j.vetimm.2021.110306 | Repeated intra-articular administration of equine allogeneic peripheral blood-derived mesenchymal stem cells does not induce a cellular and humoral immune response in horses |
| https://doi.org/10.1016/j.prevetmed.2021.105469 | Decision tree analysis for pathogen identification based on circumstantial factors in outbreaks of bovine respiratory disease in calves |
| https://doi.org/10.1200/jco.2017.35.15_suppl.2504 | Phase I first-in-man trial of a novel bromodomain and extra-terminal domain (BET) inhibitor (BI 894999) in patients (Pts) with advanced solid tumors. |
| https://doi.org/10.1016/j.rmed.2015.02.005 | A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease |
| https://doi.org/10.1200/jco.2012.30.15_suppl.tps649 | LUX-breast 1: Randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment. |
| https://doi.org/10.3389/fvets.2021.789293 | Cellular and Humoral Immunogenicity Investigation of Single and Repeated Allogeneic Tenogenic Primed Mesenchymal Stem Cell Treatments in Horses Suffering From Tendon Injuries |
| https://doi.org/10.1111/evj.14008 | Equine allogeneic tenogenic primed mesenchymal stem cells: A clinical field study in horses suffering from naturally occurring superficial digital flexor tendon and suspensory ligament injuries |
| https://doi.org/10.1186/s13075-023-03168-7 | Low-dose xenogeneic mesenchymal stem cells target canine osteoarthritis through systemic immunomodulation and homing |
| https://doi.org/10.1089/scd.2022.0296 | Intravenous Injection of Equine Mesenchymal Stem Cells in Dogs with Articular Pain and Lameness: A Feasibility Study |
| https://doi.org/10.1007/s00408-024-00778-z | Continued Treatment with Nintedanib in Patients with Progressive Pulmonary Fibrosis: Data from INBUILD-ON |
| https://doi.org/10.1111/resp.14452 | Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the |
| https://doi.org/10.3389/fvets.2024.1282697 | Safety assessment of equine allogeneic tenogenic primed mesenchymal stem cells in horses with naturally occurring tendon and ligament injuries |
| https://doi.org/10.1016/j.ejca.2023.04.007 | Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial |
| https://doi.org/10.1136/annrheumdis-2023-eular.897 | POS1329 DESIGN OF A PHASE III, RANDOMISED, PLACEBO-CONTROLLED TRIAL OF BI 1015550 IN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE |
| https://doi.org/10.1086/320998 | The Steady‐State Pharmacokinetics of Efavirenz and Nevirapine When Used in Combination in Human Immunodeficiency Virus Type 1–Infected Persons |
| https://doi.org/10.1007/s00280-015-2860-2 | A phase I study of volasertib combined with afatinib, in advanced solid tumors |
| https://doi.org/10.1007/s00280-015-2914-5 | A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors |
| https://doi.org/10.1136/annrheumdis-2021-eular.1401 | POS0687 A RANDOMISED DOSE RANGING, PLACEBO-CONTROLLED, PHASE II STUDY ASSESSING THE EFFICACY AND SAFETY OF BI 655064, AN ANTAGONISTIC ANTI-CD40 ANTIBODY, IN PATIENTS WITH LUPUS NEPHRITIS |
| https://doi.org/10.1200/jco.2012.30.15_suppl.3018 | Phase I trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors. |
| https://doi.org/10.1111/j.1742-1241.2001.tb11007.x | CARDIAC SAFETY IN THE EUROPEAN STROKE PREVENTION STUDY 2 (ESPS2) |
| https://doi.org/10.1016/s1043-6618(02)00146-9 | HEPATOTOXICITY FOLLOWING NEVIRAPINE-CONTAINING REGIMENS IN HIV-1-INFECTED INDIVIDUALS |
| https://doi.org/10.1016/j.vprsr.2020.100450 | Coprological survey of endoparasite infections in owned dogs and owners' perceptions of endoparasite control in Belgium and the Netherlands |
| https://doi.org/10.1016/j.reprotox.2015.05.010 | Juvenile animal testing of hydroxypropyl-β-cyclodextrin in support of pediatric drug development |
| https://doi.org/10.1200/jco.2009.27.15_suppl.3556 | A phase I dose finding study of the 3-day administration of BIBW 2992, an irreversible dual EGFR/HER-2 inhibitor, in combination with three-weekly docetaxel in patients with advanced solid tumors |
| https://doi.org/10.1183/13993003.congress-2019.rct1881 | Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial |
| https://doi.org/10.1007/s10637-020-01054-6 | A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma |
| https://doi.org/10.1200/jco.2015.33.3_suppl.tps794 | LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies. |
| https://doi.org/10.3389/fvets.2022.1035175 | Homing of radiolabelled xenogeneic equine peripheral blood-derived MSCs towards a joint lesion in a dog |
| https://doi.org/10.1097/00005344-199311000-00006 | Systemic and Renal Hemodynamic Responses to Carvedilol and Metoprolol in Hypertensive Renal Transplant Patients |
| https://doi.org/10.1158/0008-5472.sabcs-09-5062 | BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor for the Treatment of Patients with HER2-Negative Metastatic Breast Cancer after Failure of No More Than Two Prior Chemotherapies. |
| https://doi.org/10.1016/j.clml.2015.04.046 | Phase III randomized trial of volasertib combined with low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged ≥65 years with previously untreated, acute myeloid leukemia (AML) ineligible for intensive remission induction therapy |
| https://doi.org/10.1007/s004310050611 | Study of the bronchodilating effect of three doses of nebulized oxitropium bromide in asthmatic preschool children using the forced oscillation technique |
| https://doi.org/10.1093/annonc/mdw435.12 | gastrointestinal tumours, colorectal Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study |
| https://doi.org/10.1093/annonc/mdv234.04 | PD-005 Combined analysis of two randomised Phase II trials comparing the efficacy and safety of nintedanib versus sorafenib in Caucasian and Asian patients with advanced hepatocellular carcinoma |
| https://doi.org/10.1055/s-0039-3403297 | Nintedanib in patients with chronic fibrosing Interstitial lung diseases with progressive phenotype: the INBUILD trial* |
| https://doi.org/10.1183/13993003.congress-2020.4576 | Does nintedanib have the same effect on FVC decline in patients with progressive fibrosing ILDs treated with DMARDs or glucocorticoids? |
| https://doi.org/10.1002/vetr.2235 | Cross‐sectional study of primary antimicrobial treatment and vaccination coverage in outbreaks of bovine respiratory disease on dairy and beef farms in northern Belgium |
| https://doi.org/10.1183/13993003.congress-2023.pa2874 | Continued nintedanib treatment in patients with progressive pulmonary fibrosis: data from INBUILD-ON |
| https://doi.org/10.1002/ehf2.14891 | Heart Failure Patients' Perspectives on Treatment Outcomes and Unmet Medical Needs: A Qualitative Preference Study |
| https://doi.org/10.1183/23120541.00310-2024 | Objective measurement of cough in pulmonary fibrosis: a cohort study – ImpaCT |
| https://doi.org/10.1016/j.vetimm.2023.110547 | Immunogenicity analysis of BPV-1 positive equine sarcoid-derived cultured fibroblasts |
| https://doi.org/10.3389/fimmu.2023.1252374 | Xenogeneic equine stem cells activate anti-tumor adaptive immunity in a 4T1-based intraductal mouse model for triple-negative breast cancer: proof-of-principle |
| https://doi.org/10.1183/13993003.congress-2024.pa672 | Design of the FIBRONEER-ON open-label extension trial of nerandomilast (BI 1015550) |
| https://doi.org/10.1179/acb.2010.022 | ARE ACE-INHIBITORS OR ARB’S STILL NEEDED FOR CARDIOVASCULAR PREVENTION IN HIGH RISK PATIENTS? INSIGHTS FROM PROFESS AND TRANSCEND |
| https://doi.org/10.1136/thoraxjnl-2015-207770.144 | P7 Interim analysis of nintedanib in an open-label extension of the INPULSIS® trials (INPULSIS®-ON) |
| https://doi.org/10.1200/jco.2013.31.15_suppl.2521 | Phase I study of volasertib (BI 6727) combined with afatinib (BIBW 2992) in advanced solid tumors. |
| https://doi.org/10.1136/annrheumdis-2020-eular.3668 | THU0189 EFFICACY AND SAFETY OF NINTEDANIB IN PATIENTS WITH AUTOIMMUNE DISEASE-RELATED INTERSTITIAL LUNG DISEASE TREATED WITH DMARDS AND/OR GLUCOCORTICOIDS AT BASELINE |
| https://doi.org/10.1016/j.scr.2022.102963 | Assessing the functional properties of tenogenic primed mesenchymal stem cells in ex vivo equine tendon and ligament explants: A preliminary study |
| A phase I dose finding study of a 3-day administration of BIBW 2992, an irreversible dual EGFR/HER2 inhibitor, in combination with 3-weekly docetaxel in patients with advanced solid tumors | |
| https://doi.org/10.1016/j.jval.2017.08.951 | Market Access of Nintedanib for Idiopathic Pulmonary Fibrosis: A Cross-Country Review of Access Conditions |
| https://doi.org/10.1136/annrheumdis-2023-eular.2018 | OP0238 IMMUNOSUPPRESSION WITH TARGETED DMARDS REDUCES MORBIDITY AND MORTALITY IN PRE-CAPILLARY PULMONARY HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS: A EUSTAR ANALYSIS |
| https://doi.org/10.1158/1535-7163.targ-13-b281 | Abstract B281: Phase I study of two dosing schedules of BI 847325, an orally administered dual inhibitor of MEK and aurora kinase B, in patients with advanced solid tumors. |
| https://doi.org/10.1136/annrheumdis-2017-eular.5849 | FRI0411 Coadministration of bosentan has no effect on the pharmacokinetics of nintedanib |
| https://doi.org/10.1016/j.jval.2017.08.889 | Systematic Review of The Cost-Effectiveness of Medicines For The Treatment of Idiopathic Pulmonary Fibrosis |
| https://doi.org/10.1136/annrheumdis-2020-eular.2322 | SAT0157 NINTEDANIB DOSE ADJUSTMENTS AND ADVERSE EVENTS IN PATIENTS WITH PROGRESSIVE AUTOIMMUNE DISEASE-RELATED INTERSTITIAL LUNG DISEASES IN THE INBUILD TRIAL |
| https://doi.org/10.1200/jco.2015.33.15_suppl.tps3625 | LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies. |
| https://doi.org/10.1081/jas-120023495 | Fenoterol Delivery by Respimat® Soft Mist Inhaler Versus CFC Metered Dose Inhaler: Cumulative Dose-Response Study in Asthma Patients |
| https://doi.org/10.1007/s003920170164 | Führt hochdosiertes Dipyridamol in der sekundären Schlaganfallprävention zu kardialen Ereignissen? |
| https://doi.org/10.1007/bf00194396 | Dose-response study of oxitropium bromide inhaled as a nebulised solution |
| https://doi.org/10.1179/acb.2008.025 | LESSONS FROM ONTARGET |
| https://doi.org/10.1093/fampra/10.2.118 | The Influence of a Desk-top Analyser on the Number of Laboratory Tests used in Daily General Practice. A Randomized Controlled Trial |
| https://doi.org/10.1016/j.rmr.2015.10.215 | Étude d’extension en ouvert des essais Inpulsis® (Inpulsis®–ON) sur le nintédanib dans la fibrose pulmonaire idiopathique : analyse intermédiaire |
| Self-preservation in the face of regulatory adversity. | |
| https://doi.org/10.1093/annonc/mdv472.111 | LUME-Colon 1: a randomized phase III study of nintedanib vs placebo in patients with advanced colorectal cancer |
| https://doi.org/10.1055/s-0036-1571997 | Interim analysis of nintedanib in an open-label extension of the INPULSIS® trials (INPULSIS®-ON) |
| https://doi.org/10.1093/annonc/mdx363.002 | Biomarker prevalence study and phase I trial of afatinib in children with malignant tumours |
| https://doi.org/10.1016/j.rmra.2019.11.086 | Nintédanib chez les patients atteints de pneumopathie interstitielle diffuse (PID) chroniques avec un phénotype de fibrose progressive : essai INBUILD |
| https://doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1506 | Safety and Tolerability of Nintedanib in Patients with Fibrosing ILDs: A Comparison of the INBUILD and INPULSIS Trials |
| https://doi.org/10.1093/ndt/gfab140.001 | FC 049A RANDOMISED DOSE RANGING, PLACEBO-CONTROLLED, PHASE II STUDY ASSESSING THE EFFICACY AND SAFETY OF BI 655064, AN ANTAGONISTIC ANTI-CD40 ANTIBODY, IN PATIENTS WITH LUPUS NEPHRITIS |
| https://doi.org/10.1183/13993003.congress-2021.pa2538 | Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON |
| https://doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a5345 | Safety, Tolerability and Pharmacokinetics of BI 1015550 in Healthy Male Subjects |
| https://doi.org/10.1111/resp.13699_249 | MIPAF STUDY: MALAYSIAN OBSERVATIONAL STUDY TO DESCRIBE IDIOPATHIC PULMONARY FIBROSIS (IPF) BASELINE PRESENTATION AND OUTCOME WITH ANTI FIBROTIC |
| https://doi.org/10.1055/s-0042-1747743 | Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON* |
| https://doi.org/10.1183/13993003.congress-2022.604 | Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON |
| https://doi.org/10.1055/s-0041-1723307 | Does nintedanib have the same effect on FVC decline in patients with progressive fibrosing ILDs treated with DMARDs or glucocorticoids?* |
| https://doi.org/10.1136/annrheumdis-2024-eular.1765 | POS1300 DEMOGRAPHICS AND BASELINE CHARACTERISTICS OF PATIENTS WITH AUTOIMMUNE DISEASE INTERSTITIAL LUNG DISEASE ENROLLED IN THE FIBRONEER-ILD TRIAL OF BI 1015550 |